ST. LOUIS, MO--(Marketwired - December 05, 2013) -
The Ophthalmic Mutual Insurance Company (OMIC) has revised its consent forms related to glaucoma filtering surgery, for the first time acknowledging the exclusive FDA-approved status of Mobius Therapeutics' Mitosol® (mitomycin for solution) Kit for Ophthalmic Use
in glaucoma filtering surgery.
"This is an important step in ensuring patient and physician awareness of the FDA-approved status of critical medications," said Ed Timm, President and CEO of Mobius Therapeutics. "In the past, physicians did not have a choice with respect to antimetabolites, requiring consent for the off-label use of a highly potent substance. With the approved status of Mitosol® now communicated clearly to the patient, both the patient and surgeon can avoid the inherent risks of compounding pharmacies and compounded sterile medications."
OMIC is a member-owned mutual insurance company, sponsored by the American Academy of Ophthalmology. "Mobius applauds the foresight of OMIC in communicating this policy to their insured and their patients," Timm said.
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri. Full prescribing information for Mitosol® can be found at www.MobiusTherapeutics.com